BeGraft Aortic Stents: A European Multi-Centre Experience Reporting Acute Safety and Efficacy Outcomes for the Treatment of Vessel Stenosis in Congenital Heart Diseases.
Micol RebonatoMara PilatiSophie Malekzadeh MilaniDamien BonnetEmma PascallMatthew I JonesPedro BetrianLisa BiancoHugues LucronSébastien HascoetAlban-Elouen BaruteauLuca GiugnoGianfranco ButeraPublished in: Journal of cardiovascular development and disease (2024)
The BeGraft stent can be used safely and effectively in a wide spectrum of congenital heart diseases. Whether these good results will be stable in the longer term still needs to be investigated in a follow-up given its recent introduction into clinical practice, in particular regarding stent fracture or neointimal proliferation.
Keyphrases
- clinical practice
- aortic dissection
- liver failure
- preterm infants
- aortic valve
- signaling pathway
- respiratory failure
- left ventricular
- type diabetes
- vascular smooth muscle cells
- pulmonary artery
- adverse drug
- emergency department
- smooth muscle
- gestational age
- atomic force microscopy
- mass spectrometry
- extracorporeal membrane oxygenation
- angiotensin ii
- single molecule
- electronic health record